2MD
2MD is an orally active vitamin D analog. 2MD stimulates periosteal bone formation and decreases trabecular bone resorption. Thus 2MD restores trabecular and cortical bone mass and strength. 2MD also regulates intraocular pressure (IOP)-relative genes and reduces IOP in non-human primates.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 213250-70-5
- Formel: C27H44O3
- Molecular Weight:416.64
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | ED50 |
0.08 nM
Compound: 2, 2MD
|
Induction of human HL60 cell differentiation after 4 days by NBT reduction assay
Induction of human HL60 cell differentiation after 4 days by NBT reduction assay
|
[PMID: 22490010] |
| HL-60 | ED50 |
1.5 x 10-10M
Compound: 6b
|
Induced differentiation of human promyelocyte HL-60 cells into monocytes
Induced differentiation of human promyelocyte HL-60 cells into monocytes
|
[PMID: 9804706] |
2MD (0.5-10 ng/kg, 0,1 mL/day; p.o.; once daily for 16 weeks) not only restores both trabecular and cortical bone mass, but also increases bone mass and strength in osteopenic ovariectomized (OVX) rats by stimulating bone formation on the periosteal surface and decreasing bone resorption on the trabecular surface in rats[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ovariectomized (OVX) rats model (Sprague-Dawley female rats; 4-month-old)[2]
-
Dosage:0.5, 1, 2.5, 5, and 10 ng/kg, 0,1 mL/day
-
Administration:Oral gavage; once daily for 16 weeks
-
Result:Significantly increased serum calcium at 2.5, 5, or 10 ng/kg/day.
Dose-dependent reduction in osteoclast number and trabecular osteoclast surface, and dose-dependent increased in periosteal bone formation.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 213250-70-5
-
Molecular Weight 416.64
-
Formel C27H44O3
-
SMILES
C[C@@]12[C@](CC[C@]2([H])[C@@H](C)CCCC(C)(O)C)([H])/C(CCC1)=C/C=C3C[C@H](C([C@@H](C\3)O)=C)O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
[1]. Kutuzova GD, et al. 1α,25-Dihydroxyvitamin D(3) and its analog, 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (2MD), suppress intraocular pressure in non-human primates. Arch Biochem Biophys. 2012 Feb 1;518(1):53-60. [Content Brief]
[2]. Ke HZ, et al. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J Bone Miner Res. 2005 Oct;20(10):1742-55. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
2MD Related Classifications
HY-148698 Related Classifications
Powered by Bioz